Skip to main content

Advertisement

SpringerLink
Log in

Tetranectin as a potential novel prognostic biomarker in anthracycline-related cardiac dysfunction

  • Original Article
  • Published:
Heart and Vessels Aims and scope Submit manuscript

Abstract

To assess the association of serum tetranectin levels with cardiac remodeling parameters and to evaluate its prognostic role in women with anthracycline-related cardiac dysfunction (ARCD) and without previous cardiovascular diseases (CVD) during 24-month follow-up period. A total of 362 women with primary diagnosed breast cancer who were planned to be treated with anthracyclines were examined. At 12 months after chemotherapy completion, all women were examined and ARCD was diagnosed in 114 patients. After 24 months of follow-up, all patients with ARCD were divided into 2 groups: group 1 comprised women with the adverse course of ARCD (n = 54), group 2 comprised those without it (n = 60). In group 1, the levels of tetranectin were lower than group 2 by 27.6% (p < 0.001) and the patients without ARCD by 33.7% (p < 0.001). In group 1, the levels of tetranectin decreased (p < 0.001) from 11.8 (7.1; 14.3) to 9.02 (5.3; 14.6) pg/mL at 24 months. Moreover, in group 2 (p = 0.871) and in patients without ARCD (p = 0.716), they did not change. The tetranectin values were the independent predictor (odds ratio 7.08; p < 0.001) and its levels ≤ 15/9 ng/mL (AUC = 0.764; p < 0.001) were identified as the predictors for the adverse course of ARCD. NT-proBNP levels did not show the prognostic role, but the addition of NT-proBNP improved prognostic value of analysis (AUC = 0.954; p = 0.002). The cut-off values of tetranectin were established as predictor for adverse course of ARCD, when NT-proBNP was not. The combined use of tetranectin and NT-proBNP demonstrated higher diagnostic value for prediction of adverse outcomes.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

Data availability

The data presented in this study are available on request from the corresponding author. The data are not publicly available due to privacy.

References

  1. Herrmann J, Lenihan D, Armenian S, Barac A, Blaes A, Cardinale D, Carver J, Dent S, Ky B, Lyon AR, López-Fernández T, Fradley MG, Ganatra S, Curigliano G, Mitchell JD, Minotti G, Lang NN, Liu JE, Neilan TG, Nohria A, O’Quinn R, Pusic I, Porter C, Reynolds KL, Ruddy KJ, Thavendiranathan P, Valent P (2022) Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statement. Eur Heart J 43(4):280–299

    Article  PubMed  Google Scholar 

  2. Feijen EAML, Font-Gonzalez A, Van der Pal HJH, Kok WEM, Geskus RB, Ronckers CM, Bresters D, van Dalen EC, van Dulmen-den BE, van den Berg MH, van der Heiden-van der Loo M, van den Heuvel-Eibrink MM, van Leeuwen FE, Loonen JJ, Neggers SJCMM, Versluys ABB, Tissing WJE, Kremer LCM, DCOG‐LATER Study Group (2019) Risk and temporal changes of heart failure among 5-year childhood cancer survivors: a DCOG-LATER Study. J Am Heart Assoc 8(1):e009122

    Article  PubMed  Google Scholar 

  3. Lyon AR, López-Fernández T, Couch LS, Asteggiano R, Aznar MC, Bergler-Klein J, Boriani G, Cardinale D, Cordoba R, Cosyns B, Cutter DJ, de Azambuja E, de Boer RA, Dent SF, Farmakis D, Gevaert SA, Gorog DA, Herrmann J, Lenihan D, Moslehi J, Moura B, Salinger SS, Stephens R, Suter TM, Szmit S, Tamargo J, Thavendiranathan P, Tocchetti CG, van der Meer P, van der Pal HJH, ESC Scientific Document Group (2022) 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J 43(41):4229–4244

    Article  PubMed  Google Scholar 

  4. Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, Deswal A, Drazner MH, Dunlay SM, Evers LR, Fang JC, Fedson SE, Fonarow GC, Hayek SS, Hernandez AF, Khazanie P, Kittleson MM, Lee CS, Link MS, Milano CA (2022) 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation 145:e895–e1032

    PubMed  Google Scholar 

  5. Grakova EV, Shilov SN, Kopeva KV, Berezikova EN, Popova AA, Neupokoeva MN, Ratushnyak ET, Teplyakov AT (2022) Extracellular matrix remodeling in anthracycline-induced cardiotoxicity: what place on the pedestal? Int J Cardiol 350:55–61

    Article  PubMed  Google Scholar 

  6. McDonald K, Glezeva N, Collier P, O’Reilly J, O’Connell E, Tea I, Russell-Hallinan A, Tonry C, Pennington S, Gallagher J, Ledwidge M, Baugh J, Watson CJ (2020) Tetranectin, a potential novel diagnostic biomarker of heart failure, is expressed within the myocardium and associates with cardiac fibrosis. Sci Rep 10:7507

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Clemmensen I, Petersen LC, Kluft C (1986) Purification and characterization of a novel, oligomeric, plasminogen kringle 4 binding protein from human plasma: tetranectin. Eur J Biochem 156(2):327–333

    Article  CAS  PubMed  Google Scholar 

  8. Christensen L, Clemmensen I (1991) Differences in tetranectin immunoreactivity between benign and malignant breast tissue. Histochemistry 95:427–433

    Article  CAS  PubMed  Google Scholar 

  9. Rahim M, Rahim Z, Ahmad W, Bakri M, Dzafir I, Hashim O (2018) Inverse changes in plasma tetranectin and titin levels in patients with type 2 diabetes mellitus: a potential predictor of acute myocardial infarction? Acta Pharmacol Sin 39:1197–1207

    Article  PubMed  PubMed Central  Google Scholar 

  10. Abulaizi M, Tomonaga T, Satoh M, Sogawa K, Matsushita K, Kodera Y, Obul J, Takano S, Yoshitomi H, Miyazaki M, Nomura F (2011) The application of a three-step proteome analysis for identification of new biomarkers of pancreatic cancer. Int J Proteomics 2011:628787

    Article  PubMed  PubMed Central  Google Scholar 

  11. Kamper EF, Kopeikina LT, Koutsoukos V, Stavridis J (1997) Plasma tetranectin levels and disease activity in patients with rheumatoid arthritis. J Rheumatol 24:262–268

    CAS  PubMed  Google Scholar 

  12. Kamper EF, Kopeikina L, Mantas A, Stefanadis C, Toutouzas P, Stavridis J (1998) Tetranectin levels in patients with acute myocardial infarction and their alterations during thrombolytic treatment. Ann Clin Biochem 35(Pt3):400–407

    Article  PubMed  Google Scholar 

  13. Dardé VM, de la Cuesta F, Dones FG, Alvarez-Llamas G, Barderas MG, Vivanco F (2010) Analysis of the plasma proteome associated with acute coronary syndrome: does a permanent protein signature exist in the plasma of ACS patients? J Proteome Res 9(9):4420–4432

    Article  PubMed  Google Scholar 

  14. Panagiotopoulos I, Palatianos G, Michalopoulos A, Chatzigeorgiou A, Prapas S, Kamper EF (2010) Alterations in biomarkers of endothelial function following on-pump coronary artery revascularization. J Clin Lab Anal 24(6):389–398

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Yin X, Subramanian S, Hwang SJ, O’Donnell CJ, Fox CS, Courchesne P, Muntendam P, Gordon N, Adourian A, Juhasz P, Larson MG, Levy D (2014) Protein biomarkers of new-onset cardiovascular disease: prospective study from the systems approach to biomarker research in cardiovascular disease initiative. Arterioscler Thromb Vasc Biol 34(4):939–945

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Chan BYH, Roczkowsky A, Cho WJ, Poirier M, Sergi C, Keschrumrus V, Churko JM, Granzier H, Schulz R (2021) MMP inhibitors attenuate doxorubicin cardiotoxicity by preventing intracellular and extracellular matrix remodelling. Cardiovasc Res 117(1):188–200

    Article  CAS  PubMed  Google Scholar 

  17. Moreira-Costa L, Barros AS, Lourenço AP, Leite-Moreira AF, Nogueira-Ferreira R, Thongboonkerd V, Vitorino R (2021) Exosome-derived mediators as potential biomarkers for cardiovascular diseases: a network approach. Proteomes 9(1):8

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Barallobre-Barreiro J, Radovits T, Fava M, Mayr U, Lin WY, Ermolaeva E, Martínez-López D, Lindberg EL, Duregotti E, Daróczi L, Hasman M, Schmidt LE, Singh B, Lu R, Baig F, Siedlar AM, Cuello F, Catibog N, Theofilatos K, Shah AM, Crespo-Leiro MG, Doménech N, Hübner N, Merkely B, Mayr M (2021) Extracellular matrix in heart failure: role of ADAMTS5 in proteoglycan remodeling. Circulation 144(25):2021–2034

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Høgdall CK, Nørgaard-Pedersen B, Mogensen O (2002) The prognostic value of pre-operative serum tetranectin, CA-125 and a combined index in women with primary ovarian cancer. Anticancer Res 22(3):1765–1768

    PubMed  Google Scholar 

  20. Kopeva KV, Grakova EV, Shilov SN, Berezikova EN, Popova AA, Neupokoeva MN, Ratushnyak ET, Teplyakov AT (2022) Anthracycline-induced cardiotoxicity in women without cardiovascular diseases: molecular and genetic predictors. Acta Cardiol 77(9):805–814

    Article  CAS  PubMed  Google Scholar 

  21. Grakova EV, Shilov SN, Kopeva KV, Berezikova EN, Popova AA, Neupokoeva MN, Ratushnyak ET, Teplyakov AT (2021) Anthracycline-induced cardiotoxicity: the role of endothelial dysfunction. Cardiology 146(3):315–323

    Article  CAS  PubMed  Google Scholar 

  22. Ky B, Putt M, Sawaya H, French B, Januzzi JL Jr, Sebag IA, Plana JC, Cohen V, Banchs J, Carver JR, Wiegers SE, Martin RP, Picard MH, Gerszten RE, Halpern EF, Passeri J, Kuter I, Scherrer-Crosbie M (2014) Early increases in multiple biomarkers predict subsequent cardiotoxicity in patients with breast cancer treated with doxorubicin, taxanes, and trastuzumab. J Am Coll Cardiol 63(8):809–816

    Article  CAS  PubMed  Google Scholar 

  23. Lakhani HV, Pillai SS, Zehra M, Dao B, Tirona MT, Thompson E, Sodhi K (2021) Detecting early onset of anthracyclines-induced cardiotoxicity using a novel panel of biomarkers in West-Virginian population with breast cancer. Sci Rep 11(1):7954

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Nielsen BB, Kastrup JS, Rasmussen H, Holtet TL, Graversen JH, Etzerodt M, Thøgersen HC, Larsen IK (1997) Crystal structure of tetranectin, a trimeric plasminogen-binding protein with an alpha-helical coiled coil. FEBS Lett 412(2):388–396

    Article  CAS  PubMed  Google Scholar 

  25. Wewer UM, Ibaraki K, Schjørring P, Durkin ME, Young MF, Albrechtsen R (1994) A potential role for tetranectin in mineralization during osteogenesis. J Cell Biol 127(6 Pt 1):1767–1775

    Article  CAS  PubMed  Google Scholar 

  26. Nielsen H, Clemmensen I, Kharazmi A (1993) Tetranectin: a novel secretory protein from human monocytes. Scand J Immunol 37(1):39–42

    Article  CAS  PubMed  Google Scholar 

  27. Christensen L, Clemmensen I (1989) Tetranectin immunoreactivity in normal human tissues. An immunohistochemical study of exocrine epithelia and mesenchyme. Histochemistry 92(1):29–35

    Article  CAS  PubMed  Google Scholar 

  28. Hogdall CK, Hogdall EV, Hording U, Clemmensen I, Norgaard-Pedersen B, Toftager-Larsen K (1993) Pre-operative plasma tetranectin as a prognostic marker in ovarian cancer patients. Scand J Clin Lab Invest 53(7):741–674

    Article  CAS  PubMed  Google Scholar 

  29. Mogues T, Etzerodt M, Hall C, Engelich G, Graversen JH, Hartshorn KL (2004) Tetranectin binds to the kringle 1–4 form of angiostatin and modifies its functional activity. J Biomed Biotechnol 2:73–78

    Article  Google Scholar 

  30. Iba K, Hatakeyama N, Kojima T, Murata M, Matsumura T, Wewer UM, Wada T, Sawada N, Yamashita T (2009) Impaired cutaneous wound healing in mice lacking tetranectin. Wound Repair Regen 17(1):108–112

    Article  PubMed  Google Scholar 

  31. Chen Y, Han H, Yan X, Ding F, Su X, Wang H, Chen Q, Lu L, Zhang R, Jin W (2015) Tetranectin as a potential biomarker for stable coronary artery disease. Sci Rep 5:17632

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Weber KT, Sun Y, Guarda E, Katwa LC, Ratajska A, Cleutjens JP, Zhou G (1995) Myocardial fibrosis in hypertensive heart disease: an overview of potential regulatory mechanisms. Eur Heart J 16(Suppl C):24–28

    Article  PubMed  Google Scholar 

  33. Ho JE, Lyass A, Courchesne P, Chen G, Liu C, Yin X, Hwang SJ, Massaro JM, Larson MG, Levy D (2018) Protein biomarkers of cardiovascular disease and mortality in the community. J Am Heart Assoc 7(14):e008108

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

None.

Funding

There is no funding.

Author information

Authors and Affiliations

  1. Department of Myocardial Pathology, Cardiology Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, 111a Kievskaya Str., Tomsk, 634012, Russian Federation

    Kristina V. Kopeva, Elena V. Grakova & Alexander T. Teplyakov

  2. Department of Pathological Physiology and Clinical Pathophysiology, Novosibirsk State Medical University, Novosibirsk, Russian Federation

    Sergey N. Shilov, Ekaterina N. Berezikova & Elena T. Bobyleva

Authors
  1. Kristina V. Kopeva
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Elena V. Grakova
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Sergey N. Shilov
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ekaterina N. Berezikova
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Elena T. Bobyleva
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Alexander T. Teplyakov
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

All authors provided important intellectual contribution to the work: KK contributed to design, data collection, analysis, and drafted the first version of the manuscript, and revising for important intellectual content; EG and AT supervised research work and contributed to conception, design and data interpretation; SS and EB contributed to drafting the manuscript, crafting the discussion, and revising for important intellectual content; EB contributed to conception of the work revised for important intellectual content. All authors carefully read the manuscript and gave final approval. All authors have participated in the work and have reviewed and agree with the content of the article. None of the article contents are under consideration for publication in any other journal or have been published in any journal. No portion of the text has been copied from other material in the literature (unless in quotation marks, with citation). I am aware that it is the authors’ responsibility to obtain permission for any figures or tables reproduced from any prior publications, and to cover fully any costs involved. Such permission must be obtained prior to final acceptance.

Corresponding author

Correspondence to Kristina V. Kopeva.

Ethics declarations

Conflict of interest

Authors do not have any conflict of interest, relationships (personal, academic or financial relationships that could influence their actions) or financial involvement with an organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript.

Ethical approval

The authors state that they have obtained appropriate approval of the local Ethics Committee and have followed the principles outlined in the Declaration of Helsinki for all human research. Informed consent has been obtained from the participants involved.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kopeva, K.V., Grakova, E.V., Shilov, S.N. et al. Tetranectin as a potential novel prognostic biomarker in anthracycline-related cardiac dysfunction. Heart Vessels 38, 1256–1266 (2023). https://doi.org/10.1007/s00380-023-02277-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00380-023-02277-2

Keywords

Search

Navigation